Abstract
AbstractPrion diseases are fatal neurodegenerative disorders which are characterized by aggregations of a misfolded protein (called PrPsc) coming from its cellular isoform PrPc, mainly in brain tissue. Due to the transmissibility of this agent, every suspected case has to be monitored and reported to health authorities. Prion diseases diagnosis is a major public health issue, while the definite diagnostic is still based on post-mortem neuropathological examination. CSF biomarkers are an integral part of the diagnostic criteria and are important for the disease surveillance. The 14-3-3 detection is the first CSF surrogate biomarker helping in probable CJD classification. Despite many efforts for specific PrPsc detection, only recent technological development of assays based on protein amplification allowed to detect it in the CSF. However, reference centers have to manage this innovative technology in high security facilities (level 3). Then, nowadays, these protein amplification assays need to be optimized and standardized before their use in current practice.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
